Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cormedix ( (CRMD) ) has provided an update.
On August 7, 2025, CorMedix Inc. announced its entry into a merger agreement with Melinta Therapeutics, which is expected to close in September 2025. The merger will result in Melinta becoming a wholly owned subsidiary of CorMedix. The transaction, valued at $260 million in cash and $40 million in common shares, is subject to regulatory approvals and customary closing conditions. CorMedix plans to fund the acquisition through a combination of existing cash and a $150 million convertible notes offering. The acquisition is anticipated to enhance CorMedix’s market position and expand its product offerings, potentially benefiting stakeholders by leveraging Melinta’s existing products and pipeline.
The most recent analyst rating on (CRMD) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Cormedix stock, see the CRMD Stock Forecast page.
Spark’s Take on CRMD Stock
According to Spark, TipRanks’ AI Analyst, CRMD is a Neutral.
Cormedix’s overall stock score is influenced by a challenging financial position, marked by ongoing losses and negative cash flows. Despite technical indicators showing potential downward pressure, the recent earnings call provides a positive outlook with record-breaking revenue and strategic growth initiatives. However, valuation concerns and operational challenges remain significant obstacles.
To see Spark’s full report on CRMD stock, click here.
More about Cormedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The company is primarily focused on commercializing its lead product, DefenCath, which is used in both inpatient and outpatient settings.
Average Trading Volume: 1,988,508
Technical Sentiment Signal: Strong Buy
Current Market Cap: $897.2M
Learn more about CRMD stock on TipRanks’ Stock Analysis page.